Valneva (NASDAQ:VALN) Stock Price Down 5.6% - What's Next?

Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price traded down 5.6% during mid-day trading on Friday . The stock traded as low as $6.55 and last traded at $6.54. 19,989 shares traded hands during trading, a decline of 64% from the average session volume of 54,825 shares. The stock had previously closed at $6.93.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Valneva in a research report on Friday, January 31st.

Valneva Price Performance

The company has a fifty day moving average price of $4.63 and a two-hundred day moving average price of $5.63. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a market cap of $636.27 million, a price-to-earnings ratio of -60.23 and a beta of 1.98.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA bought a new stake in shares of Valneva SE (NASDAQ:VALN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 19,244 shares of the company's stock, valued at approximately $84,000. Institutional investors and hedge funds own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.